Carl Zeiss Meditec Shares Plunge Amidst Deepening Profit Crisis

The medical technology firm Carl Zeiss Meditec finds itself navigating a severe financial storm. A disastrous beginning to its 2025/26 fiscal year and a subsequent withdrawal of its annual forecast have sent its share price tumbling to levels not witnessed in a decade. As profit margins evaporate and the CEO position remains unfilled, investors are grappling with a pivotal question: is this a temporary setback or a sign of fundamental collapse?

A Strategic Shift Forced by Market Pressures

At the heart of the company’s struggles is its performance in China, a region accounting for approximately one-quarter of total revenue. Once a reliable growth engine, the Chinese market has now become a significant headwind. A combination of geopolitical tensions and intensifying local competition is squeezing the business.

State procurement tenders, in particular, are creating severe pricing pressure for intraocular lenses. In response, CFO Justus Felix Wehmer announced a strategic pivot: to remain competitive, Carl Zeiss Meditec plans to accelerate the localization of its production directly within China. This move is deemed essential to realign the company’s cost structure with the new market reality.

Quarterly Results Reveal Severe Strain

The first-quarter financial report lays bare the extent of the operational crisis. Revenue saw a moderate decline of nearly 5%, falling to €467 million. However, the operating result experienced a catastrophic drop. EBITA plummeted to just €8.1 million, a stark fall from over €35 million in the prior-year period.

Should investors sell immediately? Or is it worth buying Carl Zeiss Meditec?

The resulting operating margin of a meager 1.7% clarifies why management pulled its annual guidance as early as January. The original target of a 12.5% margin now appears unattainable. Compounding these issues, the company anticipates further charges of around €8 million in the current second quarter related to the write-down of obsolete inventory.

Analyst Sentiment Sours as Share Price Hits Lows

The capital market has reacted with pronounced disappointment to this mix of operational weakness and a leadership vacuum, with the search for a permanent CEO ongoing. Trading recently at €27.10, the stock is far below its 52-week high of nearly €70 and even touched a fresh ten-year low of €25.80.

Market analysts have swiftly adjusted their outlooks. Deutsche Bank cut its price target to €30, while Bernstein Research reduced its target to €28.50. Both firms maintained a cautious “hold” rating, citing excessive uncertainty over the future business trajectory. Potential bright spots, such as the launch of the “ZEISS Collaborative Care” cloud platform, are currently overshadowed by these fundamental concerns.

All Eyes on the Mid-Year Report

The next critical date for shareholders is now May 12, 2026. With the release of its half-year figures, management has promised a long-awaited update on its restructuring plans and a clarified outlook for the full fiscal year. Until then, the volatile situation in China and the absence of a permanent chief executive will continue to define the risk profile of this MDAX-listed company.